200 related articles for article (PubMed ID: 23035716)
21. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity.
Devadas B; Freeman SK; Zupec ME; Lu HF; Nagarajan SR; Kishore NS; Lodge JK; Kuneman DW; McWherter CA; Vinjamoori DV; Getman DP; Gordon JI; Sikorski JA
J Med Chem; 1997 Aug; 40(16):2609-25. PubMed ID: 9258368
[TBL] [Abstract][Full Text] [Related]
22. Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).
Pidathala C; Amewu R; Pacorel B; Nixon GL; Gibbons P; Hong WD; Leung SC; Berry NG; Sharma R; Stocks PA; Srivastava A; Shone AE; Charoensutthivarakul S; Taylor L; Berger O; Mbekeani A; Hill A; Fisher NE; Warman AJ; Biagini GA; Ward SA; O'Neill PM
J Med Chem; 2012 Mar; 55(5):1831-43. PubMed ID: 22364416
[TBL] [Abstract][Full Text] [Related]
23. KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
González-Bacerio J; Maluf SEC; Méndez Y; Pascual I; Florent I; Melo PMS; Budu A; Ferreira JC; Moreno E; Carmona AK; Rivera DG; Alonso Del Rivero M; Gazarini ML
Bioorg Med Chem; 2017 Sep; 25(17):4628-4636. PubMed ID: 28728898
[TBL] [Abstract][Full Text] [Related]
24. Molecules incorporating a benzothiazole core scaffold inhibit the N-myristoyltransferase of Plasmodium falciparum.
Bowyer PW; Gunaratne RS; Grainger M; Withers-Martinez C; Wickramsinghe SR; Tate EW; Leatherbarrow RJ; Brown KA; Holder AA; Smith DF
Biochem J; 2007 Dec; 408(2):173-80. PubMed ID: 17714074
[TBL] [Abstract][Full Text] [Related]
25. Rational Design of Proteasome Inhibitors as Antimalarial Drugs.
Le Chapelain C; Groll M
Angew Chem Int Ed Engl; 2016 May; 55(22):6370-2. PubMed ID: 27079849
[TBL] [Abstract][Full Text] [Related]
26. Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.
Gujjar R; El Mazouni F; White KL; White J; Creason S; Shackleford DM; Deng X; Charman WN; Bathurst I; Burrows J; Floyd DM; Matthews D; Buckner FS; Charman SA; Phillips MA; Rathod PK
J Med Chem; 2011 Jun; 54(11):3935-49. PubMed ID: 21517059
[TBL] [Abstract][Full Text] [Related]
27. The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs.
Herman JD; Pepper LR; Cortese JF; Estiu G; Galinsky K; Zuzarte-Luis V; Derbyshire ER; Ribacke U; Lukens AK; Santos SA; Patel V; Clish CB; Sullivan WJ; Zhou H; Bopp SE; Schimmel P; Lindquist S; Clardy J; Mota MM; Keller TL; Whitman M; Wiest O; Wirth DF; Mazitschek R
Sci Transl Med; 2015 May; 7(288):288ra77. PubMed ID: 25995223
[TBL] [Abstract][Full Text] [Related]
28. Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).
Leung SC; Gibbons P; Amewu R; Nixon GL; Pidathala C; Hong WD; Pacorel B; Berry NG; Sharma R; Stocks PA; Srivastava A; Shone AE; Charoensutthivarakul S; Taylor L; Berger O; Mbekeani A; Hill A; Fisher NE; Warman AJ; Biagini GA; Ward SA; O'Neill PM
J Med Chem; 2012 Mar; 55(5):1844-57. PubMed ID: 22364417
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, and biological and crystallographic evaluation of novel inhibitors of Plasmodium falciparum enoyl-ACP-reductase (PfFabI).
Belluti F; Perozzo R; Lauciello L; Colizzi F; Kostrewa D; Bisi A; Gobbi S; Rampa A; Bolognesi ML; Recanatini M; Brun R; Scapozza L; Cavalli A
J Med Chem; 2013 Oct; 56(19):7516-26. PubMed ID: 24063369
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and comparison of antimalarial activity of febrifugine derivatives including halofuginone.
Samant BS; Sukhthankar MG
Med Chem; 2009 May; 5(3):293-300. PubMed ID: 19442220
[TBL] [Abstract][Full Text] [Related]
31. First homology model of Plasmodium falciparum glucose-6-phosphate dehydrogenase: Discovery of selective substrate analog-based inhibitors as novel antimalarial agents.
Alencar N; Sola I; Linares M; Juárez-Jiménez J; Pont C; Viayna A; Vílchez D; Sampedro C; Abad P; Pérez-Benavente S; Lameira J; Bautista JM; Muñoz-Torrero D; Luque FJ
Eur J Med Chem; 2018 Feb; 146():108-122. PubMed ID: 29407943
[TBL] [Abstract][Full Text] [Related]
32. Drug-to-genome-to-drug, step 2: reversing selectivity in a series of antiplasmodial compounds.
Beghyn TB; Charton J; Leroux F; Henninot A; Reboule I; Cos P; Maes L; Deprez B
J Med Chem; 2012 Feb; 55(3):1274-86. PubMed ID: 22204607
[TBL] [Abstract][Full Text] [Related]
33. Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs.
Bell AS; Mills JE; Williams GP; Brannigan JA; Wilkinson AJ; Parkinson T; Leatherbarrow RJ; Tate EW; Holder AA; Smith DF
PLoS Negl Trop Dis; 2012; 6(4):e1625. PubMed ID: 22545171
[TBL] [Abstract][Full Text] [Related]
34. Probing the aurone scaffold against Plasmodium falciparum: design, synthesis and antimalarial activity.
Carrasco MP; Newton AS; Gonçalves L; Góis A; Machado M; Gut J; Nogueira F; Hänscheid T; Guedes RC; dos Santos DJ; Rosenthal PJ; Moreira R
Eur J Med Chem; 2014 Jun; 80():523-34. PubMed ID: 24813880
[TBL] [Abstract][Full Text] [Related]
35. Optimization of Physicochemical Properties for 4-Anilinoquinoline Inhibitors of Plasmodium falciparum Proliferation.
Mehta N; Ferrins L; Leed SE; Sciotti RJ; Pollastri MP
ACS Infect Dis; 2018 Apr; 4(4):577-591. PubMed ID: 29301082
[TBL] [Abstract][Full Text] [Related]
36. Characterization of Plasmodium falciparum 6-Phosphogluconate Dehydrogenase as an Antimalarial Drug Target.
Haeussler K; Fritz-Wolf K; Reichmann M; Rahlfs S; Becker K
J Mol Biol; 2018 Oct; 430(21):4049-4067. PubMed ID: 30098336
[TBL] [Abstract][Full Text] [Related]
37. In vitro resistance selections for Plasmodium falciparum dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth.
Ross LS; Gamo FJ; Lafuente-Monasterio MJ; Singh OM; Rowland P; Wiegand RC; Wirth DF
J Biol Chem; 2014 Jun; 289(26):17980-95. PubMed ID: 24782313
[TBL] [Abstract][Full Text] [Related]
38. Benzo[b]quinolizinium Derivatives Have a Strong Antimalarial Activity and Inhibit Indoleamine Dioxygenase.
Jortzik E; Zocher K; Isernhagen A; Mailu BM; Rahlfs S; Viola G; Wittlin S; Hunt NH; Ihmels H; Becker K
Antimicrob Agents Chemother; 2016 Jan; 60(1):115-25. PubMed ID: 26459907
[TBL] [Abstract][Full Text] [Related]
39. Synthesis of novel N-branched acyclic nucleoside phosphonates as potent and selective inhibitors of human, Plasmodium falciparum and Plasmodium vivax 6-oxopurine phosphoribosyltransferases.
Hocková D; Keough DT; Janeba Z; Wang TH; de Jersey J; Guddat LW
J Med Chem; 2012 Jul; 55(13):6209-23. PubMed ID: 22725979
[TBL] [Abstract][Full Text] [Related]
40. Identification, Characterization, and Optimization of 2,8-Disubstituted-1,5-naphthyridines as Novel Plasmodium falciparum Phosphatidylinositol-4-kinase Inhibitors with in Vivo Efficacy in a Humanized Mouse Model of Malaria.
Kandepedu N; Gonzàlez Cabrera D; Eedubilli S; Taylor D; Brunschwig C; Gibhard L; Njoroge M; Lawrence N; Paquet T; Eyermann CJ; Spangenberg T; Basarab GS; Street LJ; Chibale K
J Med Chem; 2018 Jul; 61(13):5692-5703. PubMed ID: 29889526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
